Med-tech firms raising money in public or private financings, including: Venus Concepts.

Biopharmas raising money in public or private financings, including: AB Science, Bioatla, Healthcare Capital, Hemostemix, Locust Walk, Qualigen, Scopus.

Med-tech firms raising money in public or private financings, including: 908 Devices, Octave Bioscience, Qiagen, Verily Life Sciences.

Biopharmas raising money in public or private financings, including: Greenwich, Vistagen.

Med-tech firms raising money in public or private financings, including: Advanced Bifurcation Systems.

Biopharmas raising money in public or private financings, including: Allterum, Baudax, Cullinan, Gamida, Harbour, Phathom, Sellas, Scynexis, Tryp, Virios.

Med-tech firms raising money in public or private financings, including: Abcellera, Adapthealth Corp., Biologics Biocardia, Carlsmed, Castle Biosciences, Endra Life Sciences, Ontrak, S-Alpha Therapeutics.

Biopharmas raising money in public or private financings, including: 4D, 9 Meters, Arvinas, Atsena, Aytu, Bioatla, Biocardia, Bone Therapeutics, Cellectis, Enveda, Exo, Forma, Junshi, Nanobiotix, Neurogene, Neuron23, Ocular Therapeutix, Phathom, Protagonist, Qualigen, Revitope, Scopus, Soligenix, Vivace.

PERTH, Australia – Chimeric Therapeutics Ltd. closed an IPO on the Australian Securities Exchange (ASX:CHM), raising AU$35 million (US$26.5 million) to fund its CAR T trial in glioblastoma.

BEIJING – Denovo Biopharma LLC closed a series D financing round to raise nearly ¥300 million (US$46 million), just six months after its $83.5 million series C round.